SciVision Biotech Inc.
TWSE:1786.TW
125.5 (TWD) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 712.988 | 557.348 | 505.539 | 466.881 | 437.873 | 329.581 | 258.418 | 228.304 | 264.842 | 158.281 | 200.509 | 200.68 | 143.271 | 66.215 | 15.682 |
| Cost of Revenue
| 200.494 | 185.481 | 163.703 | 123.604 | 132.416 | 112.66 | 105.587 | 101.149 | 109.265 | 78.795 | 84.807 | 77.504 | 52.368 | 43.123 | 28.102 |
| Gross Profit
| 512.494 | 371.867 | 341.836 | 343.277 | 305.457 | 216.921 | 152.831 | 127.155 | 155.577 | 79.486 | 115.702 | 123.176 | 90.903 | 23.092 | -12.42 |
| Gross Profit Ratio
| 0.719 | 0.667 | 0.676 | 0.735 | 0.698 | 0.658 | 0.591 | 0.557 | 0.587 | 0.502 | 0.577 | 0.614 | 0.634 | 0.349 | -0.792 |
| Reseach & Development Expenses
| 53.415 | 52.46 | 65.942 | 59.775 | 43.251 | 47.975 | 39.252 | 30.497 | 24.86 | 37.244 | 26.413 | 26.94 | 17.734 | 20.034 | 21.134 |
| General & Administrative Expenses
| 82.771 | 74.619 | 59.883 | 52.974 | 53.199 | 43.985 | 46.579 | 38.848 | 49.408 | 38.731 | 33.658 | 25.658 | 21.819 | 17.123 | 15.822 |
| Selling & Marketing Expenses
| 176.67 | 110.177 | 94.069 | 83.891 | 74.82 | 44.301 | 35.853 | 29.999 | 41.162 | 38.864 | 25.821 | 19.566 | 15.431 | 13.627 | 11.293 |
| SG&A
| 259.441 | 184.796 | 153.952 | 136.865 | 128.019 | 88.286 | 82.432 | 68.847 | 90.57 | 77.595 | 59.479 | 45.224 | 37.25 | 30.75 | 27.115 |
| Other Expenses
| 3.682 | 36.731 | -0.324 | 13.343 | 6.491 | 15.123 | -4.286 | -53.805 | 6.858 | 13.225 | 1.585 | 0.095 | 7.467 | 12.361 | 8.598 |
| Operating Expenses
| 312.856 | 237.256 | 219.894 | 196.64 | 171.27 | 136.261 | 121.684 | 99.344 | 115.43 | 114.839 | 85.892 | 72.164 | 54.984 | 50.784 | 48.249 |
| Operating Income
| 218.217 | 176.226 | 124.249 | 161.9 | 140.678 | 80.66 | 26.861 | -25.994 | 47.005 | -22.128 | 31.395 | 50.646 | 43.468 | -12.626 | -50.958 |
| Operating Income Ratio
| 0.306 | 0.316 | 0.246 | 0.347 | 0.321 | 0.245 | 0.104 | -0.114 | 0.177 | -0.14 | 0.157 | 0.252 | 0.303 | -0.191 | -3.249 |
| Total Other Income Expenses Net
| -8.22 | -2.676 | -8.194 | -9.412 | -6.401 | 12.44 | -4.191 | -5.135 | -0.233 | -0.017 | -0.031 | 0.986 | 0.291 | -1.545 | -1.586 |
| Income Before Tax
| 209.997 | 173.55 | 116.055 | 152.488 | 134.277 | 93.1 | 22.67 | -31.129 | 46.772 | -22.145 | 31.364 | 51.632 | 43.759 | -14.171 | -52.544 |
| Income Before Tax Ratio
| 0.295 | 0.311 | 0.23 | 0.327 | 0.307 | 0.282 | 0.088 | -0.136 | 0.177 | -0.14 | 0.156 | 0.257 | 0.305 | -0.214 | -3.351 |
| Income Tax Expense
| 32.097 | 31.834 | 14.335 | 24.483 | 13.574 | 6.231 | 5.531 | -4.866 | -8.068 | 0 | -8.988 | -10.798 | -7.402 | -7.307 | -0.009 |
| Net Income
| 177.9 | 141.716 | 101.72 | 128.005 | 120.703 | 86.869 | 17.139 | -26.263 | 54.84 | -22.145 | 40.352 | 62.43 | 51.161 | -6.864 | -52.535 |
| Net Income Ratio
| 0.25 | 0.254 | 0.201 | 0.274 | 0.276 | 0.264 | 0.066 | -0.115 | 0.207 | -0.14 | 0.201 | 0.311 | 0.357 | -0.104 | -3.35 |
| EPS
| 2.66 | 2.14 | 1.54 | 1.93 | 1.84 | 1.46 | 0.28 | -0.44 | 0.9 | -0.36 | 0.75 | 1.18 | 1 | -0.16 | -1.26 |
| EPS Diluted
| 2.41 | 1.92 | 1.51 | 1.88 | 1.78 | 1.46 | 0.28 | -0.44 | 0.89 | -0.36 | 0.75 | 1.18 | 1 | -0.16 | -1.26 |
| EBITDA
| 281.348 | 238.284 | 177.272 | 177.209 | 155.184 | 116.416 | 47.798 | -4.762 | 66.85 | -2.99 | 54.107 | 72.204 | 65.878 | 8.655 | -31.521 |
| EBITDA Ratio
| 0.395 | 0.428 | 0.351 | 0.38 | 0.354 | 0.353 | 0.185 | -0.021 | 0.252 | -0.019 | 0.27 | 0.36 | 0.46 | 0.131 | -2.01 |